2023
In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer
Lu L, Ma W, Johnson C, Khan S, Irwin M, Pusztai L. In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer. Vaccine 2023, 41: 2073-2083. PMID: 36813666, PMCID: PMC10064809, DOI: 10.1016/j.vaccine.2023.02.048.Peer-Reviewed Original ResearchConceptsMRNA vaccinesOvarian cancerT cell responsesMutation-derived neoantigensT cell epitopesSARS-CoV-2Multiple neoantigensCytotoxic CD8Dendritic cellsCA 125Cancer vaccinesPatient survivalImmune responseCell epitopesNeoepitope peptidesNeoantigensVaccineCell responsesCancerBreastReverse vaccinologyCD8CD40LIFNNeoepitopes
2022
Immunopathological changes, complications, sequelae and immunological memory in COVID-19 patients
Yao L, Lu L, Ma W. Immunopathological changes, complications, sequelae and immunological memory in COVID-19 patients. Heliyon 2022, 8: e09302. PMID: 35497026, PMCID: PMC9040416, DOI: 10.1016/j.heliyon.2022.e09302.Peer-Reviewed Original ResearchCOVID-19 patientsSARS-CoV-2Immunological memoryMultiple organsHealth problemsSARS-CoV-2 infectionACE2 protein levelsMultidisciplinary care teamCOVID-19 survivorsLong-term health problemsSARS-CoV-2 virusImmunopathological changesImmunological changesSevere complicationsOrgan failureModerate symptomsSevere illnessCare teamFurther managementLung tissueComplicationsPatientsDisease casesMajor organsReceptors results